Consensus $85.93M. The company said, “Ceribell (CBLL) is raising its revenue guidance for the full year 2025 to a range of $85 million to $88 million, representing growth of approximately 30% to 34% over the company’s prior year revenue.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell, Inc.: Positioned for Growth with Strong Revenue Projections and Market Expansion Opportunities
- Ceribell, Inc.’s Strategic Positioning and Patent Strength Justify Buy Rating
- Ceribell Files Patent Infringement Complaints Against Natus
- Ceribell files complaints against Natus Medical, alleges patent infringement
- Ceribell initiated with a Buy at BTIG